trending Market Intelligence /marketintelligence/en/news-insights/trending/zsbt38kouawsapejdpstpw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Allergan implant works as well as eye drops in late-stage trial

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Allergan implant works as well as eye drops in late-stage trial

Allergan PLC said its investigational biodegradable implant Bimatoprost worked as well as eye drops in reducing pressure in patients with certain eye conditions in a late-stage trial.

The phase 3 study, conducted in 594 patients with open-angle glaucoma or ocular hypertension, compared the safety and effectiveness of Bimatoprost against timolol eye drops.

Open-angle glaucoma, the most common form of glaucoma, is characterized by an increased eye pressure caused by the eye's drainage canals slowly clogging. Meanwhile, ocular hypertension is a condition characterized by higher-than-normal pressure inside the eye.

Glaucoma is one of the primary causes of irreversible vision loss and blindness.

Results of the study showed that patients who received Bimatoprost had about a 30% reduction in eye pressure over the 12-week primary efficacy period.

The Dublin-based maker of Botox noted that the early data demonstrated the potential for the majority of the patients in the trial to be treatment-free for a year after getting their last implant.

Allergan will report additional safety data from the trial, along with the results of a second phase 3 study, in the first half of 2019. The company also expects to file Bimatoprost's new drug application with the U.S. Food and Drug Administration in the second half of 2019.